IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a ...

Noting that the ultimate goal of PsA treatment is prompt reduction of ... bowel disease drives the occurrence of psoriasis or psoriatic arthritis—or whether the reverse is true.

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Arthritis is one of the most common chronic conditions affecting millions of people worldwide. Yet, many fail to recognize ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

A new study suggests that people with arthritis may be more likely to have overactive bladder (OAB), a condition that causes ...

Johnson & Johnson’s (J&J) Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults ...